Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | OGG1 | O15527 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020597 | 1.00 | LMNA (0.34) | LMNAMAPK1MAPTMEN1KMT2A | |
| SCHEMBL1022420 | 0.86 | LMNA (0.35) | LMNAMAPK1CTSSCTSKCYP1A2 | |
| SCHEMBL1022051 | 0.86 | MGLL (0.40) | LMNAMAPK1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1022421 | 0.86 | LMNA (0.35) | LMNAMAPK1CTSSCTSKCYP1A2 | |
| SCHEMBL1022053 | 0.86 | MGLL (0.40) | LMNAMAPK1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1023457 | 0.85 | CNR1 (0.39) | LMNAMAPK1MAPTCYP1A2CYP2D6 | |
| SCHEMBL1023458 | 0.85 | CNR1 (0.39) | LMNAMAPK1MAPTCYP1A2CYP2D6 | |
| SCHEMBL1019334 | 0.84 | CHRNB4 (0.36) | LMNAMAPK1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1019331 | 0.84 | CHRNB4 (0.36) | LMNAMAPK1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1021935 | 0.82 | CNR1 (0.41) | LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | claimed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | claimed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | claimed |
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | disclosed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | disclosed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | TNF, PDE4A, PDE3B | LMNA 4341/4885MAPK1 153/4885MAPT 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.